

## Curriculum vitae

update 20-08-2017

<b>name:</b>	Hendrik Gerrit van der Poel	
<b>born:</b>	9 march 1965, Rijswijk (The Netherlands)	
<b>Address</b>	Netherlands Cancer Institute Dept Urology Plesmanlaan 121 1066 CX Amsterdam The Netherlands	
<b>Education:</b>		
Medical training (MD), University of Leiden, Netherlands		1983-1990
Internship - Research fellow, dept. Neurosurgery, Richmond, Virginia, USA		1987
M.D. degree (cum laude)		23-2-1990
Thesis project: <i>Quantitative microscopy in Urological Oncology</i> Promotor: Prof. dr. F.M.J. Debruyne		1991-1993
Ph.D. degree		20-1-1994
Surgical training: Dept. of Surgery, Elisabeth Hospital, Tilburg, Netherlands		1993-1995
Scientific advisor: Urological Development and Diagnostics Laboratory, Wijchen, Netherlands		1995-1999
Urology training: Dept. Urology, Universiteit of Nijmegen, Netherlands Prof. dr. F.M.J. Debruyne		1995-1999
Dept. Urology, Canisius-Wilhelmina Hospital, Nijmegen, Netherlands Dr. H. Karthaus		1997-1998
Urology degree		1999
Fellow Dutch Cancer Foundation (Gene therapy) Brady Urol. Inst, JHU, Baltimore, USA VU-hospital, dept. Medical Oncology, Amsterdam, NL Dept. Molecular Biology, NKI, Amsterdam, NL		1999-2001
Urologist at the Antoni van Leeuwenhoek hospital / Netherlands Cancer Institute		2001-
Member of the board of the Dutch Urological Association		2002-2013
Member of the board of the European Association of Urology		2004-2008
Member of the board of the European School of Urology		2007-
Editor-in-Chief Netherlands Journal of Urology		2005-
Member of the board of the Eur. Robotic Urology Section		2012-
Editor European Urology		2012-2014
Member of the board of the EAU Prostate Cancer Guidelines panel		2015-
<b>Memberships:</b>		
European Association of Urology (EAU)		
Society of Basic Urologic Research (SBUR)		
Nederlandse Vereniging voor Urologie (NVU)		
Faculty Member of the European School of Urology (ESU)		

**Scientific publications:**First authorships:

1. van der Poel H, van Stam MA. Early or delayed radiotherapy after prostatectomy-who really benefits? *Transl Androl Urol.* 2017 Jun;6(3):593-594.
2. van der Poel HG, Wit EM, Acar C, van den Berg NS, van Leeuwen FWB, Valdes Olmos RA, Winter A, Wawroschek F, Liedberg F, Maclennan S, Lam T; Sentinel node biopsy for prostate cancer: report from a consensus panel meeting. *Sentinel Node Prostate Cancer Consensus Panel Group members. BJU Int.* 2017 Aug;120(2):204-211. doi: 10.1111/bju.13810.
3. van der Poel HG, van den Bergh RC. *Int Braz J Urol.* 2016 May-Jun;42(3):413-7. doi: 10.1590/S1677-5538.IBJU.2016.03.03. Difference of opinion - Active surveillance in intermediate risk prostate cancer: is it safe? *Opinion: Yes.*
4. van der Poel H, Brinkman W, van Cleynenbreugel B, Kallidonis P, Stolzenburg JU, Liatsikos E, Ahmed K, Brunckhorst O, Khan MS, Do M, Ganzer R, Murphy DG, Van Rij S, Dundee PE, Dasgupta P. Training in minimally invasive surgery in urology: European Association of Urology/International Consultation of Urological Diseases consultation. *BJU Int.* 2016 Mar;117(3):515-30.
5. van der Poel H, Klotz L, Stief CG. Management of low- and intermediate-risk prostate cancer. *World J Urol.* 2015 Jul;33(7):905-6.
6. van der Poel H, Klotz L, Andriole G, Azzouzi AR, Bjartell A, Cussenot O, Hamdy F, Graefen M, Palma P, Rivera AR, Stief CG. Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers. *World J Urol.* 2015 Jul;33(7):907-16.
7. van der Poel HG, van den Berg NS, KleinJan GH, van Leeuwen FW. Reply from authors re: Francesco Montorsi, Giorgio Gandaglia. Sentinel node biopsy for prostate cancer: a useless surgical exercise? *Eur urol* 2014;66:999-1000: Removing nodes that count rather than counting nodes that don't. *Eur Urol.* 2014 Dec;66(6):1000-1.
8. van der Poel HG. Extent of lymph node metastase *BJU Int.* 2014 Oct;114(4):469.
9. van der Poel HG. Nationwide prostatectomy practice. *BJU Int.* 2014 Apr;113(4):513-4.
10. van der Poel H, Tillier C, de Blok W, Acar C, van Muilekom E, van den Bergh R. Interview-based versus questionnaire-based quality of life outcomes before and after prostatectomy. *J Endourol.* 2013 Mar 20. [Epub ahead of print]
11. van der Poel HG, Beerlage HP, Klaver SO. Robotic Surgery: marking time ? *Ned Tijdschr Geneeskd.* 2013;157(28):A6365.
12. van der Poel HG, Tillier C, de Blok W, Acar C, van Muilekom EH. Salvage radiotherapy after robot-assisted laparoscopic prostatectomy. *Urology.* 2013 Oct;82(4):834-9.
13. van der Poel HG, Buckle T, Valdes Olmos R. Re: Steven Joniau, Laura Van den Bergh, Evelyne Lerut, et al. Mapping of Pelvic Lymph Node Metastases in Prostate Cancer. *Eur Urol.* 2013 Feb;63(2):e20. doi: 10.1016/j.eururo.2012.10.045. Epub 2012 Nov 2.
14. van der Poel HG, de Blok W, Tillier C, van Muilekom E. Robot-Assisted Laparoscopic Prostatectomy: Nodal Dissection Results During the First 440 Cases by Two Surgeons. *J Endourol* 2012 Dec;26(12):1618-24. doi: 10.1089.
15. van der Poel HG. Words of wisdom: Re: Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. *Eur Urol.* 2012 Jun;61(6):1266-7.
16. van der Poel HG, Balm AJ, Nieweg OE, Valdés Olmos RA. Comment on Heuveling et al.: Nanocolloidal albumin-IRDye 800CW: a near-infrared fluorescent tracer with optimal retention in the sentinel lymph node. *Eur J Nucl Med Mol Imaging.* 2012 Sep;39(9):1510-1. Epub 2012 Apr 24.
17. van der Poel H, Tillier C, de Blok W, van Muilekom E. Extended nodal dissection reduces sexual function recovery after robot assisted laparoscopic prostatectomy. *J Endourol.* 2012 Sep;26(9):1192-8.
18. van der Poel HG. Superextended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. *Eur Urol.* 2012

- Jun*;61(6):1266-7.
19. van der Poel HG, Balm AJ, Nieweg OE, Valdés Olmos RA. Comment on Heveling et al.: nanocolloidal albumin-IRDye 800CW : a near infra-red fluorescent tracer with optimal retention in the sentinel lymph node. *Eur J Nucl Med Mol Imaging*. 2012 Apr 24
  20. van der Poel HG, Buckle T, Brouwer OR, Valdés Olmos RA, van Leeuwen FW. Intraoperative Laparoscopic Fluorescence Guidance to the Sentinel Lymph Node in Prostate Cancer Patients: Clinical Proof of Concept of an Integrated Functional Imaging Approach Using a Multimodal Tracer. *Eur Urol*. 2011 Oct;60(4):826-33.
  21. Van der Poel HG, Joniau S. Adjuvant and salvage radiation for advanced prostate cancer: a discussion during the ESOU 2010 meeting. *Eur Urol Suppl* 2010;9:401-405.
  22. Van der Poel HG, Korse CM, van Tinteren H, Bergman AM, Bonfrer J. Prognostic value of serum chromogranin-A levels in men with prostate cancer. *BJU.org Online* <http://www.bju.org/ContentFullItem.aspx?id=557&LinkTypeID=1&SectionType=1>, 2010
  23. Van der Poel HG, J. Zevenhoven, A. Bergman. Pim1 regulates androgen-dependent survival signaling in prostate cancer cells. *Urol Int, Urol Int*. 2010;84(2):212-220.
  24. Van der Poel HG, J. E. van Muilekom, W. de Blok. Robot assisted laparoscopic prostatectomy: tips and tricks. *Minerva Urol Nefrol*. 2009 Dec;61(4):351-62
  25. Van der Poel HG, Words of Wisdom Re: Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Tran C, Ouk S, Clegg NJ, et al. *Eur Urol*. 2009 Sep;56(3):575.
  26. Van der Poel HG. Editorial Comment on: A Randomized Phase I Study of Testosterone Replacement for Patients with Low-Risk Castration-Resistant Prostate Cancer. *Eur Urol*. 2009 Feb 27.
  27. Van der Poel HG. Chemical castration and survival in low risk prostate cancer. *Eur Urol* 2009 Apr. 1.
  28. Van der Poel HG, W. de Blok, N. Joshi, E. van Muilekom. Preservation of the lateral prostatic fascia is associated with urine continence after robotic-assisted prostatectomy. *Eur Urol*. 2009 Apr;55(4):892-900.
  29. Van der Poel HG, W. de Blok. Role of the extent of fascia preservation and erectile function after robot-assisted laparoscopic prostatectomy. *Urology*. 2009 Apr;73(4):816-21
  30. Van der Poel HG, Moonen L, Horenblas S. Sequential treatment for recurrent localised prostate cancer. *J Surg Oncol* 2008, 97:377-382.
  31. Van der Poel HG, de Blok W, Bex A, Meinhardt W, Horenblas S. Peroperative transrectal ultrasound (peTRUS) accelerates the learning curve of robot assisted laparoscopic prostatectomy (RALP). *BJU* 2008 102:849-852.
  32. Van der Poel HG. Editorial Comment on: Predictive Value of the Differential Expression of the Urokinase Plasminogen Activation Axis in Radical Prostatectomy Patients. *Eur Urol* 2008, Jun 23.
  33. Van der Poel HG. Editorial Comment on: Oncological and Functional Results of Antegrade Radical Retropubic Prostatectomy for the Treatment of Clinically Localised Prostate Cancer. *Eur Urol*. 2008 Mar;53(3):561-2.
  34. Van der Poel HG. Radionuclide treatment in metastasized prostate cancer. *EAU-EBU update series* 2007 5:113-125.
  35. Van der Poel HG. Editorial Comment on: Marked Gene Transcript Level Alterations Occur Early During Radical Prostatectomy. *Eur Urol*. 2008 Feb;53(2):344..
  36. Van der Poel HG. Cytoskeleton Fragments Unveiling Bladder Cancer. *Eur Urol* 2007 May;51(5):1162-3.
  37. Van der Poel HG. Molecular markers in the diagnosis of prostate cancer. *Crit Rev Oncol Hematol*. 2007 61:104-139.
  38. Van der Poel HG, Beetsma DB, van Boven H, Horenblas S. Perineal Salvage Prostatectomy for Radiation Resistant Prostate Cancer. *Eur Urol*. 2006
  39. Van der Poel HG, E. Bais. Case report: Capecitabine in a patient with hormone refractory cancer of the prostate with neuroendocrine differentiation and elevated CEA. *Netherlands Journal of Urology*, 2006;1:13-16.
  40. Van der Poel HG. Foreseeing cancer metastases. *Eur Urol*. 2006 Oct;50(4):648-9.
  41. Van der Poel HG, Antonini N, Hoefnagel CA, Horenblas S, Valdés Olmos RA. Serum hemoglobin levels predict response to strontium-89 and rhenium-186-HEDP radionuclide treatment for painful osseous metastases in prostate cancer. *Urol Int* 2006;77(1):50-56.
  42. Van der Poel HG, Horenblas S. Transition zone biopsies of the prostate fail to detect many

- tumors located to that part of the prostate. *Netherlands Journal of Urology*, 2006;3:81-85.
43. Van der Poel HG, Meinhardt W. Seminal vesicle biopsy and treatment choice for localized prostate cancer. *Netherlands Journal of Urology*, 2005;8:202-208.
  44. Van der Poel HG, Antonini N, Hoefnagel CA, Horenblas S, Valdes Olmos RA. Strontium-89 and Rhenium-186 radionuclide treatment for painful osseous metastases in prostate cancer. *Netherlands Journal of Urology*, 2005;6:20-25.
  45. Van der Poel HG. Androgen receptor and TGFbeta1 / Smad signaling are mutually inhibitory in prostate cancer. *Eur Urol* 2005;48:1051-1058.
  46. Van der Poel HG, Antonini N, van Tinteren H, Horenblas S. Upper urinary tract cancer: Location is correlated with prognosis. *Eur Urol* 2005;48:435-444.
  47. Van der Poel HG, Teertstra HJ, Horenblas S. Unexpected histology after nephrectomy for presumed renal or urothelial cell carcinoma. *Netherlands Journal of Urology*, 2005;5:
  48. Van der Poel HG, Horenblas S. Bicalutamide dosing in patients with rising PSA under maximal androgen blockade (MAB). *Netherlands Journal of Urology* 2004;4:107-111.
  49. Van der Poel HG. Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-beta1 in prostate cancer cells. *J Urol* 2004;172:1333-1337.
  50. Van der Poel HG. Smart drugs in prostate cancer. *Eur Urol* 2004;45:1-17.
  51. Van der Poel HG, Hanrahan C, Zhong H, Simons J. Rapamycin induces Smad activity in prostate cancer cell lines. *Urol Res* 2003;30:380-386.
  52. Van der Poel HG, Molenaar B, van Beusechem VW, Haisma HJ, Rodriguez R, Curiel DT, Gerritsen WR. Epidermal growth factor receptor targeting of replication competent adenovirus enhances cytotoxicity in bladder cancer. *J Urol*. 2002;168:266-272.
  53. Van der Poel HG, McCadden J, Verhaegh GW, Kruszewski M, Ferrer F, Schalken JA, Carducci M, Rodriguez R. A novel method for the determination of basal gene expression of tissue-specific promoters: an analysis of prostate-specific promoters. *Cancer Gene Therapy* 2001;8:927-935.
  54. Van der Poel HG, Debruyne FMJ. Can biological markers replace cystoscopy? An update. *Curr. Opin Urol*. 2001;11:503-509.
  55. Van der Poel HG, van Rhijn BW, Peelen P, Debruyne FMJ, Boon ME, Schalken JA. Consecutive quantitative cytology in bladder cancer. *Urology* 2000;56:584-588.
  56. Van der Poel HG, Sedelaar JPM, Debruyne FMJ, Witjes JA. Recurrence of germ cell tumor after orchiectomy. *Urology* 2000;56:467-473.
  57. Van der Poel HG: Markers for recurrence of superficial bladder cancer: what is valid? *Curr Opin Urol*. 1999; 9:401-406.
  58. Van der Poel HG, Mungan NA, Witjes JA: Bladder cancer in women. *Int Urogynecol J* 1999;10:207-212.
  59. Van der Poel HG, Roukema JA, Horenblas S, van Geel AN, Debruyne FMJ: Metastasectomy in renal carcinoma: a multicenter retrospective analysis. *Eur Urol* 1999; 35:197-203.
  60. Van der Poel HG, Hessels D, van Leenders GJLH, Bussemakers MJ, Schalken JA, Witjes JA, Debruyne FMJ. Multifocal transitional cell cancer and p53 mutation analysis. *J Urol* 1998;160:124-125.
  61. Van der Poel HG, Witjes JA, Schalken JA, Debruyne FMJ. Automated image analysis for bladder cancer. *Invited editorial. Urol Res* 1998; 26(1): 1-5.
  62. Van der Poel HG, van Balken MR, Schamhart DH, Peelen P, de Reijke T, Debruyne FM, Schalken JA, Witjes JA. Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer. *Urology* 1998;51:44-50.
  63. Van der Poel HG, Meuleman EJH. Wat is het beleid bij een steriele "stuwingsepididymitis" na vasectomie? *Vademecum* 1997;15:10.
  64. Van der Poel HG, Meuleman EJH Heeft een semenkweek bij een dubieuze epididymitis zin? *Vademecum* 1997;15:46.
  65. Van der Poel HG, Boon ME, van Stratum P, Ooms ECM, Wiener H, Debruyne

- FMJ, Witjes JA, Schalken JA, Murphy WM. Conventional bladder wash cytology performed by four experts versus quantitative image analysis. *Mod Pathol* 1997;10(10):976-982.
66. Van der Poel HG, Feitz WFJ, Bökkerink J, van der Staak F, de Vries JDM. Wilms tumor with teratomatous cysts in a horseshoe kidney: a diagnostic pitfall. *J Urol* 1997;57(5):1837-1838.
  67. Van der Poel HG, Oosterhof, GON, Schaafsma HE, Debruyne FMJ, Schalken JA. Intratumoral nuclear morphologic heterogeneity in prostate cancer. *Urology* 1997;49(4):652-657.
  68. Van der Poel HG, Witjes JA, van Stratum P, Boon ME, Debruyne FM, Schalken JA. Quanticyt: karyometric analysis of bladder washing for patients with superficial bladder cancer. *Urology* 1996;48(3):357-64.
  69. Van der Poel HG, Mulders PFA, Debruyne FMJ. Lymph node surgery in renal cell carcinoma: anatomical and therapeutic dilemmas. In: *Lymph node surgery in urology*. Ed. JP Donohue, International Society of Urology Reports. ISIS Medical Media, Oxford, 1995, pp13-20.
  70. Van der Poel HG, Mulders PF, Oosterhof GO, Schaafsma HE, Hendriks JC, Schalken JA, Debruyne. Tumor heterogeneity as prognostic factor in patients with low-stage (T1-3N0M0) renal-cell carcinoma. *Investig Urol Berl* 1994;5:60-5.
  71. Van der Poel HG, Mulders PF, Aalders TW, Oosterhof GO, Debruyne FM, Schalken JA. Karyometric analysis of intra-tumour heterogeneity in prostate adenocarcinoma. *Anal Cell Pathol* 1994;7(2):153-70.
  72. Van der Poel HG, Boon ME. Microwave-antigen retrieval for proliferation analysis (MIB-1) and quanticyt karyometry of bladder washings. *Eur J Morphol* 1994;32(1):71-8.
  73. Van der Poel HG, Oosterhof GO, Debruyne FM, Schalken JA. Image analysis in superficial transitional cell carcinoma of the bladder. *Semin Urol* 1993;11(3):164-70.
  74. Van der Poel HG, Mulders PF, Oosterhof GO, Schaafsma HE, Hendriks JC, Schalken JA, Debruyne FM. Prognostic value of karyometric and clinical characteristics in renal cell carcinoma. *Quantitative assessment of tumor heterogeneity*. *Cancer* 1993;72(9):2667-74.
  75. Van der Poel HG, Oosterhof GO, Schaafsma HE, Wiersma van Tilburg A, Debruyne FM, Schalken JA. Karyometry of bladder washings for the follow up of patients with transitional cell carcinoma of the bladder. *Prog Clin Biol Res* 1992;378:9-18.
  76. Van der Poel HG, van Caubergh RD, Boon ME, Debruyne FM, Schalken JA. Karyometry in recurrent superficial transitional cell tumors of the bladder. *Urol Res* 1992;20(5):375-81.
  77. Van der Poel HG, Schaafsma HE, Vooijs GP, Debruyne FM, Schalken JA. Quantitative light microscopy in urological oncology. *J Urol* 1992;148(1):1-13.
  78. Van der Poel HG, Boon ME, Kok LP, van der Meulen EA, van Caubergh RD, de Bruijn WC, Debruyne FM. Morphometry, densitometry and pattern analysis of plastic-embedded histologic material from urothelial cell carcinoma of the bladder. *Anal Quant Cytol Histol* 1991;13(5):307-15.
  79. Van der Poel HG, Boon ME, van der Meulen EA, Wijsman Grootendorst A. The reproducibility of cytomorphometrical grading of bladder tumours. *Virchows Arch A Pathol Anat Histopathol* 1990; 416(6): 521-5.
  80. Van der Poel HG, Boon ME, Kok LP, Tolboom J, van der Meulen B, Ooms EC. Can cytomorphometry replace histomorphometry for grading of bladder tumours? *Virchows Arch A Pathol Anat Histopathol* 1988;413(3):249-55.

Other publications (co-authorships):

1. Validation and head-to-head comparison of three nomograms predicting probability of lymph node invasion of prostate cancer in patients undergoing extended and/or sentinel lymph node dissection. Grivas N, Wit E, Tillier C, van Muilekom E, Pos F, Winter A, van der Poel H. *Eur*

J Nucl Med Mol Imaging. 2017 Aug 5. doi: 10.1007/s00259-017-3788

2. The impact of adding sentinel node biopsy to extended pelvic lymph node dissection on the biochemical recurrence of prostate cancer patients treated with robot-assisted radical prostatectomy. Grivas N, Wit E, Kuusk T, KleinJan G, Donswijk M, van Leeuwen F, van der Poel H. *J Nucl Med*. 2017 Jul 26. pii: jnumed.117.195644. doi: 10.2967/jnumed.117.195644
3. Multispectral fluorescence guided surgery; a feasibility study in a phantom using a clinical-grade laparoscopic camera system. van Willigen DM, van den Berg NS, Buckle T, KleinJan GH, Hardwick JC, van der Poel HG, van Leeuwen FW. *Am J Nucl Med Mol Imaging*. 2017 Jul 15;7(3):138-147
4. Performance of a fast and high-resolution multi-echo spin-echo sequence for prostate T2 mapping across multiple systems. van Houdt PJ, Agarwal HK, van Buuren LD, Heijmink SWTPJ, Haack S, van der Poel HG, Ghobadi G, Pos FJ, Peeters JM, Choyke PL, van der Heide UA. *Magn Reson Med*. 2017 Jul 3. doi: 10.1002/mrm.26816
5. Development and validation of a tool for non-technical skills evaluation in robotic surgery-the ICARS system. Raison N, Wood T, Brunckhorst O, Abe T, Ross T, Challacombe B, Khan MS, Novara G, Buffi N, Van Der Poel H, McIlhenny C, Dasgupta P, Ahmed K. *Surg Endosc*. 2017 Jun 20. doi: 10.1007/s00464-017-5622-x
6. Robot-assisted Laparoscopic Implantation of Brachytherapy Catheters in Bladder Cancer. Bosschieter J, Vis AN, van der Poel HG, Moonen LM, Horenblas S, van Rhijn BWG, Pieters BR, Nieuwenhuijzen JA, Hendricksen K. *Eur Urol*. 2017 Jun 12. pii: S0302-2838(17)30494-3.
7. Patterns of Benign Prostate Hyperplasia Based on Magnetic Resonance Imaging Are Correlated With Lower Urinary Tract Symptoms and Continence in Men Undergoing a Robot-assisted Radical Prostatectomy for Prostate Cancer. Grivas N, van der Roest R, Tillier C, Schouten D, van Muilekom E, Schoots I, van der Poel H, Heijmink S. *Urology*. 2017 Jun 7. pii: S0090-4295(17)30604-0.
8. Reducing the rate of biopsy Gleason undergrading may not improve biochemical recurrence rates in active surveillance candidates. van den Bergh RC, Zargar H, Heijmink S, Bozin M, Murphy DG, van der Poel HG. *Minerva Urol Nefrol*. 2017 Aug;69(4):359-365. doi: 10.23736/S0393-2249.17.02749-7.
9. A core outcome set for localised prostate cancer effectiveness trials. MacLennan S, Williamson PR, Bekema H, Campbell M, Ramsay C, N'Dow J, MacLennan S, Vale L, Dahm P, Mottet N, Lam T; COMPACTERS Study Group. *BJU Int*. 2017 Mar 27. doi: 10.1111/bju.13854
10. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, Bolla M, Briers E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouvière O. *Eur Urol*. 2017 Aug;72(2):250-266. doi: 10.1016/j.eururo.2017.02.026
11. Quantitative assessment of fascia preservation improves the prediction of membranous urethral length and inner levator distance on continence outcome after robot-assisted radical prostatectomy. Grivas N, van der Roest R, Schouten D, Cavicchioli F, Tillier C, Bex A, Schoots I, Artibani W, Heijmink S, Van Der Poel H.
12. Repeatability of dose painting by numbers treatment planning in prostate cancer radiotherapy based on multiparametric magnetic resonance imaging. van Schie MA, Steenberg P, Dinh CV, Ghobadi G, van Houdt PJ, Pos FJ, Heijmink SWTJP, van der Poel HG, Renisch S, Vik T, van der Heide UA. *Phys Med Biol*. 2017 Jun 14;62(14):5575-5588

13. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer. Tosco L, Laenen A, Briganti A, Gontero P, Karnes RJ, Albersen M, Bastian PJ, Chlosta P, Claessens F, Chun FK, Everaerts W, Gratzke C, Graefen M, Kneitz B, Marchioro G, Salas RS, Tombal B, Van den Broeck T, Moris L, Battaglia A, van der Poel H, Walz J, Bossi A, De Meerleer G, Haustermans K, Van Poppel H, Spahn M, Joniau S. *Prostate Cancer Prostatic Dis.* 2017 May 9. doi: 10.1038/pcan.2017.29
14. Prevalence and correlates of mental health problems in prostate cancer survivors: A case-control study comparing survivors with general population peers. van Stam MA, van der Poel HG, Bosch JLHR, Tillier CN, Horenblas S, Mols F, Aaronson NK. *Urol Oncol.* 2017 Aug;35(8):531.e1-531.e7. doi: 10.1016/j.urolonc.2017.03.028
15. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. Fossati N, Willemse PM, Van den Broeck T, van den Bergh RCN, Yuan CY, Briers E, Bellmunt J, Bolla M, Cornford P, De Santis M, MacPepple E, Henry AM, Mason MD, Matveev VB, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Lam TB, Mottet N, Joniau S. *Eur Urol.* 2017 Jul;72(1):84-109. doi: 10.1016/j.eururo.2016.12.003.
16. The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis. Tosco L, Laenen A, Briganti A, Gontero P, Karnes RJ, Bastian PJ, Chlosta P, Claessens F, Chun FK, Everaerts W, Gratzke C, Albersen M, Graefen M, Kneitz B, Marchioro G, Salas RS, Tombal B, Van den Broeck T, Van Der Poel H, Walz J, De Meerleer G, Bossi A, Haustermans K, Van Poppel H, Spahn M, Joniau S; European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT). *Eur Urol Focus.* 2017 Jan 17. pii: S2405-4569(17)30002-0.
17. Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. Lardas M, Liew M, van den Bergh RC, De Santis M, Bellmunt J, Van den Broeck T, Cornford P, Cumberbatch MG, Fossati N, Gross T, Henry AM, Bolla M, Briers E, Joniau S, Lam TB, Mason MD, Mottet N, van der Poel HG, Rouvière O, Schoots IG, Wiegel T, Willemse PM, Yuan CY, Bourke L. *Eur Urol.* 2017 Jul 27. pii: S0302-2838(17)30535-3.
18. From interventionist imaging to intraoperative guidance: New perspectives by combining advanced tools and navigation with radio-guided surgery. Vidal-Sicart S, Valdés Olmos R, Nieweg OE, Faccini R, Grootendorst MR, Wester HJ, Navab N, Vojnovic B, van der Poel H, Martínez-Román S, Klode J, Wawroschek F, van Leeuwen FWB. *Rev Esp Med Nucl Imagen Mol.* 2017 Aug 3. pii: S2253-654X(17)30106-3
19. Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment. van den Bergh R, Gandaglia G, Tilki D, Borgmann H, Ost P, Surcel C, Valerio M, Sooriakumaran P, Briganti A, Graefen M, van der Poel H, de la Taille A, Montorsi F, Ploussard G; European Association of Urology Young Academic Urologists Working Party on Prostate Cancer (EAU-YAUWP). *Eur Urol Focus.* 2017 Aug 8. pii: S2405-4569(17)30188-8. doi: 10.1016/j.euf.2017.07.003.
20. Endo-Urological Techniques for Benign Uretero-Ileal Strictures Have Poor Efficacy and Affect Renal Function. Fransen van de Putte EE, de Wall LL, van Werkhoven E, Heldeweg EA, Bex A, van der Poel HG, van Rhijn BWG, Horenblas S, Hendricksen K. *Urol Int.* 2017 Aug 18. doi: 10.1159/000475508
21. Modular Training for Robot-Assisted Radical Prostatectomy: Where to Begin? Lovegrove C, Ahmed K, Novara G, Guru K, Mottrie A, Challacombe B, der Poel HV, Peabody J, Dasgupta P. *J Surg Educ.* 2016 Dec 5. pii: S1931-7204(16)30284-7.
22. Vesico-urethral anastomosis (VUA) evaluation of short- and long-term outcome after robot-assisted laparoscopic radical prostatectomy (RARP): selective cystogram to improve outcome. Tillier C, van Muilekom HA, Bloos-van der Hulst J, Grivas N, van der Poel HG. *J Robot Surg.* 2017 Jan 12. doi: 10.1007/s11701-017-0677-1.

23. Sentinel Lymph Node Dissection to Select Clinically Node-negative Prostate Cancer Patients for Pelvic Radiation Therapy: Effect on Biochemical Recurrence and Systemic Progression. Grivas N, Wit E, Pos F, de Jong J, Vegt E, Bex A, Hendricksen K, Horenblas S, KleinJan G, van Rhijn B, **van der Poel H**. *Int J Radiat Oncol Biol Phys*. 2017 Feb 1;97(2):347-354. doi: 10.1016/j.ijrobp.2016.10.016.
24. Multi-center validation of prostate tumor localization using multi-parametric MRI and prior knowledge. Dinh CV, Steenbergen P, Ghobadi G, **van der Poel H**, Heijmink SW, de Jong J, Isebaert S, Haustermans K, Lerut E, Oyen R, Ou Y, Christos D, van der Heide UA. *Med Phys*. 2016 Dec 31. doi: 10.1002/mp.12086. [Epub ahead of print]
25. Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection. Moris L, Van den Broeck T, Tosco L, Van Baelen A, Gontero P, Karnes RJ, Everaerts W, Albersen M, Bastian PJ, Chlosta P, Claessens F, Chun FK, Graefen M, Gratzke C, Kneitz B, Marchioro G, Salas RS, Tombal B, **Van Der Poel H**, Walz JC, De Meerleer G, Bossi A, Haustermans K, Montorsi F, Van Poppel H, Spahn M, Briganti A, Joniau S. *Front Surg*. 2016 Dec 16;3:65. doi: 10.3389/fsurg.2016.00065.
26. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Azzouzi AR, Vincendeau S, Barret E, Cicco A, Kleinclaus F, van der Poel HG, Stief CG, Rassweiler J, Salomon G, Solsona E, Alcaraz A, Tammela TT, Rosario DJ, Gomez-Veiga F, Ahlgren G, Benzaghrou F, Gaillac B, Amzal B, Debruyne FM, Fromont G, Gratzke C, Emberton M; PCM301 Study Group. *Lancet Oncol*. 2016 Dec 19. pii: S1470-2045(16)30661-1. doi: 10.1016/S1470-2045(16)30661-1. [Epub ahead of print]
27. Competency based training in robotic surgery: benchmark scores for virtual reality robotic simulation. Raison N, Ahmed K, Fossati N, Buffi N, Mottrie A, Dasgupta P, **Van Der Poel H**. *BJU Int*. 2016 Nov 10. doi: 10.1111/bju.13710. [Epub ahead of print]
28. Sentinel node biopsy and lymphatic mapping in penile and prostate cancer. van der Poel HG, Meershoek P, Grivas N, KleinJan G, van Leeuwen FW, Horenblas S. *Urologe A*. 2017 Jan;56(1):13-17. doi: 10.1007/s00120-016-0270-7.
29. Beyond penile cancer, is there a role for sentinel node biopsy in urological malignancies? Brouwer OR, van der Poel HG, Bevers RF, van Gennep EJ, Horenblas S. *Clin Transl Imaging*. 2016;4(5):395-410. Review.
30. Sentinel Node Procedure in Prostate Cancer: A Systematic Review to Assess Diagnostic Accuracy. Wit EM, Acar C, Grivas N, Yuan C, Horenblas S, Liedberg F, Valdes Olmos RA, van Leeuwen FW, van den Berg NS, Winter A, Wawroschek F, Hruby S, Janetschek G, Vidal-Sicart S, MacLennan S, Lam TB, van der Poel HG. *Eur Urol*. 2016 Sep 14. pii: S0302-2838(16)30617-0. doi: 10.1016/j.eururo.2016.09.007.
31. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N. *Eur Urol*. 2016 Aug 31. pii: S0302-2838(16)30469-9. doi: 10.1016/j.eururo.2016.08.002.
32. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RC, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P. *Eur Urol*. 2016 Aug 25. pii: S0302-2838(16)30470-5. doi: 10.1016/j.eururo.2016.08.003.
33. Navigation of a robot-integrated fluorescence laparoscope in preoperative SPECT/CT and



- intraoperative freehand SPECT imaging data: a phantom study. van Oosterom MN, Engelen MA, van den Berg NS, KleinJan GH, van der Poel HG, Wendler T, van de Velde CJ, Navab N, van Leeuwen FW. *J Biomed Opt.* 2016 Aug 1;21(8):86008. doi: 10.1117/1.JBO.21.8.086008. No abstract available.
34. Multispectral Fluorescence Imaging During Robot-assisted Laparoscopic Sentinel Node Biopsy: A First Step Towards a Fluorescence-based Anatomic Roadmap. van den Berg NS, Buckle T, KleinJan GH, van der Poel HG, van Leeuwen FW. *Eur Urol.* 2016 Jun 23. pii: S0302-2838(16)30282-2. doi: 10.1016/j.eururo.2016.06.012.
  35. The Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer. Van der Roest RC, van Houdt PJ, Heijmink SW, de Jong J, Bergman AM, Zwart W, van der Heide UA, van der Poel HG. *Urol Case Rep.* 2016 May 26;7:67-9. doi: 10.1016/j.eucr.2016.04.010.
  36. van Oosterom MN, Simon H, Mengus L, Welling MM, van der Poel HG, van den Berg NS, van Leeuwen FW. Revolutionizing (robot-assisted) laparoscopic gamma tracing using a drop-in gamma probe technology. *Am J Nucl Med Mol Imaging.* 2016 Jan 28;6(1):1-17
  37. KleinJan GH, Bunschoten A, van den Berg NS, Olmos RA, Klop WM, Horenblas S, van der Poel HG, Wester HJ, van Leeuwen FW. Fluorescence guided surgery and tracer-dose, fact or fiction? *Eur J Nucl Med Mol Imaging.* 2016 Mar 28.
  38. van Stam MA, Aaronson NK, Pos FJ, Bosch JL, Kieffer JM, Tillier CN, van der Poel HG. The Effect of Salvage Radiotherapy and its Timing on the Health-related Quality of Life of Prostate Cancer Patients. *Eur Urol.* 2016 Mar 22. pii: S0302-2838(16)00267-0.
  39. Nevedomskaya E, Stelloo S, van der Poel HG, de Jong J, Wessels LF, Bergman AM, Zwart W. Androgen receptor DNA binding and chromatin accessibility profiling in prostate cancer. *Genom Data.* 2015 Dec 28;7:124-6. doi: 10.1016/j.gdata.2015.12.020
  40. van den Bergh RC, van der Kwast TH, de Jong J, Zargar H, Ryan AJ, Costello AJ, Murphy DG, van der Poel HG. Validation of the novel ISUP-2014 5-tier Gleason grade grouping: Biochemical recurrence rates of 3+5 disease may be overestimated. *BJU Int.* 2016 Mar 12. doi: 10.1111/bju.13478.
  41. Current training on the basics of robotic surgery in the Netherlands: Time for a multidisciplinary approach? Brinkman W, de Angst I, Schreuder H, Schout B, Draaisma W, Verweij L, Hendriks A, **van der Poel H.** *Surg Endosc.* 2017 Jan;31(1):281-287. doi: 10.1007/s00464-016-4970-2.
  42. Expectant Management for Prostate Cancer: Lessons from the Past, Challenges for the Future. van den Bergh RC, Murphy DG, van der Poel HG. *Eur Urol.* 2016 Nov;70(5):767-768. doi: 10.1016/j.eururo.2016.04.024. No abstract available
  43. Ghobadi G, de Jong J, Hollmann BG, van Triest B, van der Poel HG, Vens C, van der Heide UA Histopathology-derived modeling of prostate cancer tumor control probability: Implications for the dose to the tumor and the gland. *Radiother Oncol.* 2016 Feb 16. pii: S0167-8140(16)00073-6. doi: 10.1016/
  44. Sivaraman A, Ordaz Jurado G, Cathelineau X, Barret E, Dell'Oglio P, Joniau S, Bianchi M, Briganti A, Spahn M, Bastian P, Chun J, Chlosta P, Gontero P, Graefen M, Jeffrey Karnes R, Marchioro G, Tombal B, Tosco L, van der Poel HH, Sanchez-Salas R. Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy. *World J Urol.* 2016 Feb 20.
  45. KleinJan GH, van den Berg NS, de Jong J, Wit EM, Thygessen H, Vegt E, van der Poel HG, van Leeuwen FW. Multimodal hybrid imaging agents for sentinel node mapping as a means to (re)connect nuclear medicine to advances made in robot-assisted surgery. *Eur J Nucl Med*

Mol Imaging. 2016 Jan 15.

46. van Leeuwen FW, van der Poel HG. Surgical Guidance in Prostate Cancer: "From Molecule to Man" Translations. Clin Cancer Res. 2016 Mar 15;22(6):1304-6.
47. van den Bergh RC, van Casteren NJ, van den Broeck T, Fordyce ER, Gietzmann WK, Stewart F, MacLennan S, Dabestani S, Bellmunt J, Bolla M, Briers E, Cornford P, Joniau S, Mason MD, Matveev V, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Lam TB, Mottet N. Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review. Eur Urol. 2015 Dec 12. pii: S0302-2838(15)01178-1.
48. Reesink DJ, Fransen van de Putte EE, Vegt E, De Jong J, van Werkhoven E, Mertens LS, Bex A, van der Poel HG, van Rhijn BW, Horenblas S, Meijer RP. Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomography-Should Patients Receive Further Evaluation? J Urol. 2015 Nov 17. pii: S0022-5347(15)05239-8.
49. Lovegrove C, Novara G, Mottrie A, Guru KA, Brown M, Challacombe B, Popert R, Raza J, **Van der Poel H**, Peabody J, Dasgupta P, Ahmed K. Structured and Modular Training Pathway for Robot-assisted Radical Prostatectomy (RARP): Validation of the RARP Assessment Score and Learning Curve Assessment. Eur Urol. 2016 Mar;69(3):526-35.
50. Fuerst B, Sprung J, Pinto F, Frisch B, Wendler T, Simon H, Mengus L, van den Berg NS, van der Poel HG, van Leeuwen FW, Navab N. First Robotic SPECT for Minimally Invasive Sentinel Lymph Node Mapping. IEEE Trans Med Imaging. 2016 Mar;35(3):830-8.
51. Kerkmeijer LG, Monninkhof EM, van Oort IM, van der Poel HG, de Meerleer G, van Vulpen M. PREDICT: model for prediction of survival in localized prostate cancer. World J Urol. 2015 Sep 29.
52. Stelloo S, Nevedomskaya E, van der Poel HG, de Jong J, van Leenders GJ, Jenster G, Wessels LF, Bergman AM, Zwart W. Androgen receptor profiling predicts prostate cancer outcome. EMBO Mol Med. 2015 Sep 27;7(11):1450-64.
53. Fransen van de Putte EE, Hermans TJ, Werkhoven Ev, Mertens LS, Meijer RP, Bex A, Wassenaar AE, van der Poel HG, van Rhijn BW, Horenblas S. Lymph node count at radical cystectomy does not influence long-term survival if surgeons adhere to a standardized template. Urol Oncol. 2015 Dec;33(12):504.e19-24
54. van de Putte EE, Mertens LS, Meijer RP, van der Heijden MS, Bex A, van der Poel HG, Kerst JM, Bergman AM, Horenblas S, van Rhijn BW. Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin. World J Urol. 2016 Feb;34(2):157-62.
55. Acar C, Kleinjan GH, van den Berg NS, Wit EM, van Leeuwen FW, van der Poel HG. Advances in sentinel node dissection in prostate cancer from a technical perspective. Int J Urol. 2015 Oct;22(10):898-909.
56. Wit E, De Jong J, Acar C, Van Muilekom E, Tillier C, De Blok W, **Van Der Poel H**. Stapling for prostate pedicle management during robot assisted radical prostatectomy. Minerva Urol Nefrol. 2015 May 27.
57. Ahmed K, Khan R, Mottrie A, Lovegrove C, Abaza R, Ahlawat R, Ahlering T, Ahlgren G, Artibani W, Barret E, Cathelineau X, Challacombe B, Coloby P, Khan MS, Hubert J, Michel MS, Montorsi F, Murphy D, Palou J, Patel V, Piechaud PT, Van Poppel H, Rischmann P, Sanchez-Salas R, Siemer S, Stoeckle M, Stolzenburg JU, Terrier JE, Thüroff JW, Vaessen C, Van Der Poel HG, Van Cleynenbreugel B, Volpe A, Wagner C, Wiklund P, Wilson T, Wirth M, Witt J, Dasgupta P. Development of a standardised training curriculum for robotic surgery: a consensus statement from an international multidisciplinary group of experts. BJU Int. 2015

Jul;116(1):93-101.

58. van Rhijn BW, Catto JW, Goebell PJ, Knüchel R, Shariat SF, van der Poel HG, Sanchez-Carbayo M, Thalmann GN, Schmitz-Dräger BJ, Kiemeny LA. Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice. *Urol Oncol*. 2014 Sep 9. pii: S1078-1439
59. Domanska UM, Boer JC, Timmer-Bosscha H, van Vugt MA, Hoving HD, Kliphuis NM, Rosati S, van der Poel HG, de Jong IJ, de Vries EG, Walenkamp AM. CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model. *Clin Exp Metastasis*. 2014 Oct;31(7):829-39
60. Ploussard G, Isbarn H, Briganti A, Sooriakumaran P, Surcel CI, Salomon L, Freschi M, Mirvald C, van der Poel HG, Jenkins A, Ost P, van Oort IM, Yossepowitch O, Giannarini G, van den Bergh RC; Members of the Prostate Cancer Working Group of the Young Academic Urologists Working Party of the European Association of Urology. Can we expand active surveillance criteria to include biopsy gleason 3+4 prostate cancer? A multi-institutional study of 2323 patients. *Urol Oncol*. 2014 Aug 14. pii: S1078-1439
61. KleinJan GH, van den Berg NS, Brouwer OR, de Jong J, Acar C, Wit EM, Vegt E, van der Noort V, Valdés Olmos RA, van Leeuwen FW, van der Poel HG. Optimisation of fluorescence guidance during robot-assisted laparoscopic sentinel node biopsy for prostate cancer. *Eur Urol*. 2014 Aug 1. pii: S0302-2838
62. Hollmann BG, van Triest B, Ghobadi G, Groenendaal G, de Jong J, van der Poel HG, van der Heide UA. Gross tumor volume and clinical target volume in prostate cancer: How do satellites relate to the index lesion. *Radiother Oncol*. 2015 Mar 18. pii: S0167-8140(15)00120-6. doi: 10.1016/j.radonc.2015.01.021
63. Volpe A, Ahmed K, Dasgupta P, Ficarra V, Novara G, van der Poel H, Mottrie A. Pilot Validation Study of the European Association of Urology Robotic Training Curriculum. *Eur Urol*. 2014 Oct 31. pii: S0302-2838(14)01039-2.
64. Chícharo de Freitas JR, KleinJan GH, van der Poel HG, van den Berg NS, Vegt E, Stokkel MP, Valdés Olmos RA [Utility of SPECT/CT scan for anatomical localization of pararectal and presacral sentinel nodes in prostate cancer]. *Rev Esp Med Nucl Imagen Mol*. 2015 Jan-Feb;34(1):19-23. doi: 10
65. Ahmed K, Khan R, Mottrie A, Lovegrove C, Abaza R, Ahlawat R, Ahlering T, Ahlgren G, Artibani W, Barret E, Cathelineau X, Challacombe B, Coloby P, Khan MS, Hubert J, Michel MS, Montorsi F, Murphy D, Palou J, Patel V, Piechaud PT, Van Poppel H, Rischmann P, Sanchez-Salas R, Siemer S, Stoeckle M, Stolzenburg JU, Terrier JE, Thüroff JW, Vaessen C, Van Der Poel HG, Van Cleynenbreugel B, Volpe A, Wagner C, Wiklund P, Wilson T, Wirth M, Witt J, Dasgupta P. Development of a standardised training curriculum for robotic surgery: a consensus statement from an international multidisciplinary group of experts. *BJU Int*. 2014 Oct 31. doi: 10.1111/bju.12974.
66. Brinkman WM, Schout BM, Rietbergen JB, de Vries AH, van der Poel HG, Koldewijn EL, Witjes JA, van Merriënboer JJ. Training robotic surgery in urology: experience and opinions of robot urologists. *Int J Med Robot*. 2014 Oct 24. doi: 10.1002
67. Rouprêt M, Morgan TM, Bostrom PJ, Cooperberg MR, Kutikov A, Linton KD, Palou J, Martínez-Piñeiro L, van der Poel H, Wijburg C, Winterbottom A, Woo HH, Wirth MP, Catto JW European Association of Urology (@Uroweb) recommendations on the appropriate use of social media. *Eur Urol*. 2014 Oct;66(4):628-32. doi: 10.1016
68. Tillier CN, van Stam MA, de Blok W, van Muilekom HVM, Bloos-van der Hulst J and van der Poel HG Web-Based Quality of Life Questionnaire Followed by Paper-Based Questionnaire for the Non-Responders: Daily Practice in Patients with Prostate Cancer. *Int J Cancer Clin Res*

2015, 2:2

69. Brouwer OR, van den Berg NS, Mathéron HM, Wendler T, van der Poel HG, Horenblas S, Valdés Olmos RA, van Leeuwen FW. Feasibility of intraoperative navigation to the sentinel node in the groin using preoperatively acquired single-photon emission computerized-tomography data: transferring functional imaging to the operating room. *J Urol*. 2014 Dec;192(6):1810-6.
70. Van Den Berg NS, Buckle T, Kleinjan GI, Klop WM, Horenblas S, Van Der Poel HG, Valdés-Olmos RA, Van Leeuwen FI. Hybrid tracers for sentinel node biopsy. *Q J Nucl Med Mol Imaging*. 2014 Jun;58(2):193-206
71. Rybalov M, Ananias HJ, Hoving HD, van der Poel HG, Rosati S, de Jong IJ. PSMA, EpCAM, VEGF and GRPR as imaging targets in locally recurrent prostate cancer after radiotherapy/ *Int J Mol Sci*. 2014 Apr 10;15(4):6046-61.
72. van den Bergh RC, de Blok W, van Muilekom E, Tillier C, Venderbos LD, van der Poel HG. Impact on quality of life of radical prostatectomy after initial active surveillance: more to lose? *Scand J Urol*. 2014 Aug;48(4):367-73
73. van den Bergh RCN, Albertsen PC, Bangma CH, Freedland SJ, Graefen M, Vickers A, van der Poel HG. Timing of curative treatment for prostate cancer: a systemic review. *Eur Urol* 2013 64:204-215.
74. van den Bergh RC, van der Poel HG. Re: M. Minhaj Siddiqui, Soroush Rais-Bahrami, Hong Truong, et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. *Eur Urol* 2013;64:713-9 and Re: Mark Emberton. Has magnetic resonance-guided biopsy of the prostate become the standard of care? *Eur Urol* 2013;64:720-1. *Eur Urol*. 2014 Jun;65(6):e106-7
75. Brouwer OR, van den Berg NS, Mathéron HM, van der Poel HG, van Rhijn BW, Bex A, van Tinteren H, Valdés Olmos RA, van Leeuwen FW, Horenblas S. A hybrid radioactive and fluorescent tracer for sentinel node biopsy in penile carcinoma as a potential replacement for blue dye. *Eur Urol*. 2014 Mar;65(3):600-9.
76. Mertens LS, Meijer RP, de Vries RR, Nieuwenhuijzen JA, van der Poel HG, Bex A, van Rhijn BW, Meinhardt W, Horenblas S. Prostate Sparing Cystectomy for Bladder Cancer: 20-Year Single Center Experience. *J Urol*. 2013 Nov 25.
77. Djajadiningrat RS, van Werkhoven E, Meinhardt W, van Rhijn BW, Bex A, van der Poel HG, Horenblas S. Penile sparing surgery in penile cancer: does it affect survival? *J Urol*. 2013 Dec 24.
78. Meijer RP, Mertens LS, van Rhijn BW, Bex A, van der Poel HG, Meinhardt W, Kerst JM, Bergman AM, Fioole-Bruining A, van Werkhoven E, Horenblas S. Induction chemotherapy followed by surgery in node positive bladder cancer. *Urology*. 2014 Jan;83(1):134-9.
79. Nieuwenhuijzen JA, de Vries RR, van Tinteren H, Bex A, Van der Poel HG, Meinhardt W, Horenblas S. Follow-up after cystectomy: Regularly scheduled, risk adjusted, or symptom guided?: Patterns of recurrence, relapse presentation, and survival after cystectomy. *Eur J Surg Oncol*. 2014 Jan
80. Acar C, Schoffelmeer CC, Tillier C, de Blok W, van Muilekom E, van der Poel HG. Quality of Life in Patients with Low-Risk Prostate Cancer. A Comparative Retrospective Study: Brachytherapy Versus Robot-Assisted Laparoscopic Prostatectomy Versus Active Surveillance. *J Endourol*. 2013 Sep 27.
81. Greco F, Cadeddu JA, Gill IS, Kaouk JH, Remzi M, Thompson RH, van Leeuwen FW, van der Poel HG, Fornara P, Rassweiler J. Current Perspectives in the Use of Molecular Imaging To Target Surgical Treatments for Genitourinary Cancers. *Eur Urol*. 2013 Aug 7. doi:pii: S0302-2838(13)00748
82. Mertens LS, Meijer RP, Meinhardt W, van der Poel HG, Bex A, Kerst JM, van der Heijden MS, Bergman AM, Horenblas S, van Rhijn BW. Occult lymph node metastases in patients with

- muscle invasive bladder cancer: incidence after neoadjuvant chemotherapy and cystectomy versus cystectomy alone. *BJU Int.* 2013 Sep 5
83. Djajaningrat RS, Graafland NM, van Werkhoven E, Meinhardt W, Bex A, van der Poel HG, van Boven HH, Olmos RA, Horenblas S. Contemporary management of regional nodes in penile cancer: improvement of survival? *J Urol* 2013 Aug 2. doi:pii: S0022-5347(13)05054-4. 10.1016
  84. Buffi N, Van Der Poel H, Guazzoni G, Mottrie A; on behalf of the Junior European Association of Urology (EAU) Robotic Urology Section with the collaboration of the EAU Young Academic Urologists Robotic Section. Methods and priorities of robotic surgery training program. *Eur Urol* 2013 Jul 19. doi:pii: S0302-2838(13)00735-5. 10.1016
  85. Meijer RP, Meinhardt W, van der Poel HG, van Rhijn BW, Kerst JM, Pos FJ, Horenblas S, Bex A. Local control rate and prognosis after sequential chemoradiation for small cell carcinoma of the bladder. *Int J Urol* 2012 Dec 11. doi: 10.1111/iju.12038
  86. Meijer RP, Nieuwenhuijzen JA, Meinhardt W, Bex A, van der Poel HG, van Rhijn BW, Kerst JM, Bergman AM, van Werkhoven E, Horenblas S. Response to induction chemotherapy and surgery in non-organ confined bladder cancer: a single institute experience. *Eur J Surg Oncol.* 2013 Apr;39(4):365-71. doi: 10.1016
  87. Palou J, Wood D, Bochner BH, van der Poel H, Al-Ahmadie HA, Yossepowitch O, Soloway MS, Jenkins LC. ICUD-EAU international consultation on bladder cancer 2012: urothelial carcinoma of the prostate. *Eur Urol.* 2013 Jan;63(1):81-7. doi: 10.1016/
  88. van den Berg NS, Valdés-Olmos RA, van der Poel HG, van Leeuwen FW. Sentinel node biopsy for prostate cancer: a hybrid approach. *J Nucl Med.* 2013 Apr;54(4):493-6. doi: 10.2967/jnumed.112.113746
  89. Brouwer OR, Buckle T, Bunschoten A, Kuil J, Vahrmeijer AL, Wendler T, Valdés-Olmos RA, van der Poel HG, van Leeuwen FW. Image navigation as a means to expand the boundaries of fluorescence-guided surgery. *Phys Med Biol.* 2012 May 21;57(10):3123-36.
  90. Peters M, Moman MR, van der Poel HG, Vergunst H, de Jong IJ, Vijverberg PL, Battermann JJ, Horenblas S, van Vulpen M. Patterns of outcome and toxicity after salvage prostatectomy, salvage cryosurgery and salvage brachytherapy for prostate cancer recurrences after radiation therapy: a multi-center experience and literature review. *WJU* 2012 aug 8
  91. Mertens LS, Meijer RP, van Werkhoven E, Bex A, van der Poel HG, van Rhijn BW, Meinhardt W, Horenblas S. Differences in histopathological evaluation of standard lymph node dissections result in differences in nodal count but not in survival. *WJU* 2012 Aug 9
  92. Montorsi F, Wilson TG, Rosen RC, Ahlering TE, Artibani W, Carroll PR, Costello A, Eastham JA, Ficarra V, Guazzoni G, Menon M, Novara G, Patel VR, Stolzenburg JU, Van der Poel H, Van Poppel H, Mottrie A. Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. *Eur Urol.* 2012 Sep;62(3):368-81. Epub 2012 Jun 7
  93. Ficarra V, Novara G, Ahlering TE, Costello A, Eastham JA, Graefen M, Guazzoni G, Menon M, Mottrie A, Patel VR, Van der Poel H, Rosen RC, Tewari AK, Wilson TG, Zattoni F, Montorsi F. Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy. *Eur Urol.* 2012 Sep;62(3):418-30. Epub 2012 Jun 1.
  94. Brouwer OR, Buckle T, Vermeeren L, Klop WM, Balm AJ, van der Poel HG, van Rhijn BW, Horenblas S, Nieweg OE, van Leeuwen FW, Valdés Olmos RA. Comparing the hybrid fluorescent-radioactive tracer indocyanine green-99mTc-nanocolloid with 99mTc-nanocolloid for sentinel node identification: a validation study using lymphoscintigraphy and SPECT/CT. *J Nucl Med.* 2012 Jul;53(7):1034-40. Epub 2012 May 29.
  95. Ficarra V, Sooriakumaran P, Novara G, Schatloff O, Briganti A, Van der Poel H, Montorsi F, Patel V, Tewari A, Mottrie A. Systematic review of methods for reporting combined outcomes after radical prostatectomy and proposal of a novel system: the survival, continence, and potency (SCP) classification. *Eur Urol.* 2012 Mar;61(3):541-8. Epub 2011 Dec 2. Review.
  96. van Vugt HA, Roobol MJ, van der Poel HG, van Muilekom EH, Busstra M, Kil P, Oomens EH,

- Leliveld A, Bangma CH, Korfage I, Steyerberg EW. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study. *BJU Int.* 2012 Jul;110(2):180-7
97. Palou J, Wood D, Bochner BH, van der Poel H, Al-Ahmadie HA, Yossepowitch O, Soloway MS, Jenkins LC. ICUD-EAU International Consultation on Bladder Cancer 2012: Urothelial Carcinoma of the Prostate. *Eur Urol.* 2013 Jan;63(1):81-7. doi: 10.1016/j.eururo.2012.08.011.
  98. Brouwer OR, Buckle T, Vermeeren L, Klop WM, Balm AJ, van der Poel HG, van Rhijn BW, Horenblas S, Nieweg OE, van Leeuwen FW, Valdés Olmos RA. Comparing the hybrid fluorescent-radioactive tracer indocyanine green-99mTc-nanocolloid with 99mTc-nanocolloid for sentinel node identification: a validation study using lymphoscintigraphy and SPECT/CT. *J Nucl Med.* 2012 May 29.
  99. Buckle T, Brouwer OR, Valdés Olmos RA, van der Poel HG, van Leeuwen FW. Relationship between intraprostatic tracer deposits and sentinel lymph node mapping in prostate cancer patients. *J Nucl Med.* 2012 May 29.
  100. van Leeuwen AC, Buckle T, Bendle G, Vermeeren L, Valdés Olmos R, van der Poel HG, van Leeuwen FW. Tracer-cocktail injections for combined pre- and intraoperative multimodal imaging of lymph nodes in a spontaneous mouse prostate tumor model. *J Biomed Opt.* 2011 Jan-Feb;16(1):016004
  101. Nacerddine K, Beaudry JB, Ginja V, Westerman B, Mattioli F, Song JY, van der Poel H, Ponz OB, Pritchard C, Cornelissen-Steijger P, Zevenhoven J, Tanger E, Sixma TK, Ganesan S, van Lohuizen M. Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer. *J Clin Invest.* 2012 May 1;122(5):1920-32.
  102. Meijer RP, Nunnink CJ, Wassenaar AE, Bex A, van der Poel HG, van Rhijn BW, Meinhardt W, Horenblas S. Standard lymph node dissection for bladder cancer: significant variability in the number of reported lymph nodes. *J Urol.* 2012 Feb;187(2):446-50.
  103. van den Berg NS, van Leeuwen FW, van der Poel HG. Fluorescence guidance in urologic surgery. *Curr Opin Urol.* 2012 Mar;22(2):109-20.
  104. van Vugt HA, Kranse R, Steyerberg EW, van der Poel HG, Busstra M, Kil P, Oomens EH, de Jong IJ, Bangma CH, Roobol MJ. Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort. *Eur J Cancer.* 2012 Mar 7.
  105. de Vries RR, Kauer P, van Tinteren H, van der Poel HG, Bex A, Meinhardt W, van Haarst EP, Horenblas S. Short-Term Outcome after Cystectomy: Comparison of Two Different Perioperative Protocols. *Urol Int.* 2012;88(4):383-9.
  106. Nunnink CJ, de Vries RR, Meinhardt W, van der Poel HG, Bex A, Horenblas S. Pregnancy following sexuality-preserving cystectomy for bladder cancer. *Ned Tijdschr Geneeskd.* 2011;155:A2820.
  107. Ficarra V, Sooriakumaran P, Novara G, Schatloff O, Briganti A, Van der Poel H, Montorsi F, Patel V, Tewari A, Mottrie A. Systemic review of methods for reporting combined outcomes after radical prostatectomy and proposal of a novel system: the survival, continence, and potency (SCP) classification. *Eur Urol.* 2012 Mar;61(3):541-8.
  108. Meinhardt W, van der Poel HG, Valdés Olmos RA, Bex A, Brouwer OR, Horenblas S. Laparoscopic sentinel node biopsy for prostate cancer: the relevance of locations outside the extended dissection area. *Prostate Cancer.* 2012;2012:751753
  109. Hinnen KA, Schaapveld M, van Vulpen M, Battermann JJ, van der Poel H, van Oort IM, van Roermund JG, Monninkhof EM. Prostate brachytherapy and second primary cancer risk: a comparative risk analysis. *J Clin Oncol.* 2011 Dec 1;29(34):4510-5.
  110. Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B, van der Poel H. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. *Eur Urol.* 2011 Nov;60(5):1045-54.
  111. Chade DC, Shariat SF, Cronin AM, Savage CJ, Karnes RJ, Blute ML, Briganti A, Montorsi F, van der Poel HG, Van Poppel H, Joniau S, Godoy G, Hurtado-Coll A, Gleave ME, Dall'oglio M,


- Srougi M, Scardino PT, Eastham JA. Salvage radical prostatectomy for radiation recurrent prostate cancer: a multi-institutional collaboration. *Eur Urol.* 2011 Aug;60(2):205-10.
112. Roef MJ, van der Poel HG, van der Laken CJ, Vogel WV. Colchicine must be stopped before imaging with [18F]-methylcholine PET/CT. *Nucl Med Commun* 2010 12:1075
113. Steggerda MJ, van der Poel HG, Moonen LM. Minimizing the number of implantation needles for prostate (125)I brachytherapy: an investigation of possibilities and implications. *Brachytherapy.* 2010 9(4):319-27.
114. Graafland NM, Valdés Olmos RA, Meinhardt W, Bex A, van der Poel HG, van Boven HH, Nieweg OE, Horenblas S. Nodal staging in penile carcinoma by dynamic sentinel node biopsy after previous therapeutic primary tumour resection. *Eur Urol.* 2010 Jul 13.
115. Vermeeren L, Meinhardt W, van der Poel HG, Valdés Olmos RA. Lymphatic drainage from the treated versus untreated prostate: feasibility of sentinel node biopsy in recurrent prostate cancer. *Eur J Nucl Med Mol Imaging.* 2010 Nov;37(11):2021-6.
116. Moman MR, van der Poel HG, Battermann JJ, Moerland MA, van Vulpen M. Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrence after primary 125-I implantation and external beam radiotherapy. *Brachytherapy.* 2010 Apr-Jun;9(2):119-25
117. Vermeeren L, Meinhardt W, Bex A, van der Poel HG, Vogel WV, Hoefnagel CA, Horenblas S, Valdés Olmos RA. Para-aortic sentinel lymph nodes: toward optimal detection and intraoperative localization using SPECT/CT and intraoperative real-time imaging. *J Nucl Med.* 2010 Mar;51(3):376-82.
118. Pizzocaro G., Algaba F., Horenblas S., Solsona E., Tana S., Van der Poel H., Watkin N.A. EAU penile cancer guidelines. *Eur Urol.* 2010 Jun;57(6):1002-12
119. Joshi N, de Blok W, van Muilekom E., van der Poel HG. Impact of posterior fascia musculofascial reconstruction on early continence after robot-assisted laparoscopic radical prostatectomy: results of a prospective parallel group trial. *Eur Urol.* 2010 Jul;58(1):84-9.
120. Murphy DG, Bjartell A, Ficarra V, Graefen M, Haese A, Montironi R, Montoris F, Moul JW, Novara G, Sauter G, Sulser T, van der Poel HG. Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. *Eur Urol.* 2010 May;57(5):735-46.
121. Vermeulen E, Schmidt MK, Aaronson NK, Kuenen M, Baas-Vrancken Peeters MJ, van der Poel H. Horenblas S, Boot H, Verwaal VJ, Cats A, van Leeuwen FE. A trial of consent procedures for future research with clinically derived biological samples. *Br J Cancer.* 2009 Nov 3;101(9):1505-12.
122. van den Bergh RC, Vasarainen H, van der Poel HG, Vis-Maters JJ, Rietbergen JB, Pickles T, Cornel EB, Valdagni R, Jaspars JJ, van der Hoeven J, Staerman F, Oomens EH, Rannikko A, Roemeling S, Steyerberg EW, Roobol MJ, Schröder FH, Bangma CH. Short-term outcomes of the prospective multicentre 'prostate cancer research international: active surveillance' study. *BJU Int.* 2010 Apr;105(7):956-62.
123. de Vries RR, Nieuwenhuijzen JA, van Tinteren H, Oddens JR, Visser O, van der Poel HG, Bex A, Meinhardt W, Horenblas S. Prostate-sparing cystectomy: long-term oncological results. *BJU Int.* 2009 Nov;104(9):1239-43.
124. Vermeeren L, Valdés Olmos RA, Meinhardt W, Bex A, van der Poel HG, Vogel WV, Sivo F, Hoefnagel CA, Horenblas S. Value of SPECT/CT for detection and anatomic localization of sentinel lymph node before laparoscopic sentinel node lymphadenectomy in prostate carcinoma. *J Nucl Med.* 2009 Jun;50(6):865-70.
125. Steggerda M, van der Poel HG, Moonen LMF. An analysis of the relation between physical characteristics of prostate I-125 seed implants and lower urinary tract symptoms: bladder hotspot dose and prostate size are significant predictors. *Radiother Oncol* 2008 88:108-114.
126. Vermeeren L, Valdés Olmos RA, Meinhardt W, Bex A, van der Poel HG, Vogel WV, Sivo F, Hoefnagel CA, Horenblas S.. Intraoperative radioguidance with a

- portable gamma camera: a novel technique for laparoscopic sentinel node localisation in urological malignancies. *Eur J Nucl Med Mol Imaging*. 2009 Jul;36(7):1029-36.
127. Meinhardt W, Valdes Olmos RA, van der Poel HG, Bex A, Horenblas S. Laparoscopic sentinel node dissection for prostate carcinoma: technical and anatomical observations. *BJU Int*. 2008 Sep;102(6):714-7.
128. Nawijn MA, Bergman A.M., van der Poel H.G. Genetically engineered mouse models for prostate cancer. *EEUS* 2008 7:566-575.
129. M.J. Steggerda, H.G. van der Poel, L.M.F. Moonen. Predicting urinary morbidity after brachytherapy of localized prostate cancer. *EAU-ABU Update Serie* 2008.
130. Nieuwenhuijzen JA, de Vries RR, Bex A, van der Poel HG, Meinhardt W, Antonini N, Horenblas S. Urinary diversions after cystectomy: the association of clinical factors, complications and functional results of four different diversions. *Eur Urol*. 2008 Apr;53(4):834-42
131. Mol AJM, Geldof AA, Meijer GA, van der Poel HG, Moorselaar van RJA. New experimental markers for early detection of high-risk prostate cancer: role of cell-cell adhesion and cell migration. *J Cancer Res Clin Oncol*. 2007 Oct;133(10):687-95.
132. Steggerda MJ, Moonen LM, van der Poel HG, Schneider CJ. The influence of geometrical changes on the dose distribution after I-125 seed implantation of the prostate. *Radiother Oncol*. 2007 Apr;83(1):11-7
133. Barendrecht MM, Mulders AC, van der Poel H, van der Hoff MJ, Schmidt M, Michel MC. Role of transforming growth factor {beta} in rat bladder smooth muscle cell proliferation. *J Pharmacol Exp Ther*. 2007;322:117-122
134. Steggerda MJ, van der Poel HG, Moonen LMF. Is er een verband tussen mictieklachten en dosisverdeling na implantatie van de prostaat met I-125 zaadjes? *Ned Tijdschr Urol* 2006;14:159-61
135. Kroon BK, Valdes Olmos RA, van der Poel HG, Nieweg OE, Horenblas S. Prepubic sentinel node location in penile carcinoma. *Clin Nucl Med*. 2005;30:649-650.
136. Steggerda M, Schneider C, van Herk M, Zipp L, Moonen L, van der Poel HG. The applicability of simultaneous TRUS-CT imaging for the evaluation of prostate seed implants. *Med Phys* 2005;32:2262-2270.
137. Kroon BK, Horenblas S, Meinhardt W, van der Poel HG, Bex A, van Tinteren H, Valdes Olmos R, Nieweg OE. Dynamic sentinel node biopsy in penile carcinoma: evaluation of 10 years experience. *Eur Urol* 2005;47:601-605.
138. van Rhijn B, van der Poel HG, van der Kwast Th. Urine markers for bladder cancer surveillance. A systemic review. *Eur Urol* 2005, 47(6):736-748.
139. Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. *Cancer Gene Therapy* 2004;8:1-21.
140. Sachs MD, Ramamurthy M, van der Poel H, Wickham TJ, Lamfers M, Gerritsen W, Chowdhury W, Li Y, Schoenberg MP, Rodriguez R. Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (car) preferentially in bladder cancer cells. *Cancer Gene Therapy* 2004;11:477-486.
141. Spermon JR, Roeleveld TA, van der Poel HG, Hulsbergen-van de Kaa CA, Ten Bokkel Huinink WW, van de Vijver M, Witjes JA, Horenblas S. Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors. *Urology* 2002;59:923-929.
142. Zhong H, Hanrahan C, van der Poel HG, Simons JW. Hypoxia-inducible factor 1alpha and 1beta proteins share common signaling pathways in human prostate cancer cells. *Biochem Biophys Res Commun*. 2001, 284:352-356.
143. Sedelaar JP, van Leenders GJ, Hulsbergen-van de Kaa CA, van der Poel HG, van der Laak JA, Debruyne FMJ, Wijkstra H, de la Rosette JJ. Microvessel density: correlation between contrast ultrasonography and histology of prostate cancer. *Eur Urol* 2001, 40:285-293.
144. DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M, Hamper U,



- DeJong R, Detorie N, Rodriguez R, Haulk T, DeMarzo AM, Piantadosi S, Yu DC, Chen Y, Henderson DR, Carducci MA, Nelson WG, Simons JW. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. *Cancer Res* 2001, 61:7464-7472.
145. Schalken J, Visakorpi T, Thalmann G, van der Poel HG. Molecular biology for urologists. *Eur Urol Curric Urol* 2001, 7.2:1-11.
146. Vriesema JL, van der Poel HG, Debruyne FMJ, Schalken JA, Kok LP, Boon ME. Neural network-based digitized cell image diagnosis of bladder wash cytology. *Diagn Cytopathol* 2000;23:171-179.
147. Mungan NA, Kiemeny LA, van Dijk JA, van der Poel HG, Witjes JA. Gender differences in stage distribution of bladder cancer. *Urology* 55:368-371, 2000.
148. van Rhijn BW, van der Poel HG, Boon ME, Debruyne FMJ, Schalken JA, Witjes JA. Presence of carcinoma in situ and high 2c-deviation index are the best predictors of invasive transitional cell carcinoma of the bladder in patients with high-risk quanticyt. *Urology* 55:363-367, 2000.
149. Debruyne FMJ, van der Poel HG. Clinical experience in Europe with Uroselective alpha1-antagonists. *Eur Urol* 1999;36 Suppl S1:54-58.
150. Debruyne FMJ, Akaza H, Fitzpatrick JM, Mahler C, Motta M, Thrasher JB, Tunn UW, Varkarakis M, van der Poel HG. Secondary hormonal therapy in prostate cancer. Consensus Meeting on Prostate Cancer. Paris, June 1999.
151. d'Ancona FCH, Albers YHM, Kiemeny LA, Xue Y, Smedts F, van der Poel HG, Debruyne FMJ, de la Rosette JJMCH. Can histopathology predict treatment outcome following high-energy transurethral microwave thermotherapy of the prostate? Results of a biopsy study. *Prostate* 1999;40:28-36.
152. Xue Y, van der Laak JAWM, Latijnhouwers MAHE, Smedts F, van der Poel HG, de la Rosette JJMCH, Debruyne FMJ, Schalken JA. Transient tenascin enhancement is an early event after androgen ablation in rat prostate. *Urol Res* 1999;27:9-15.
153. Vet JAM, Hessels D, Marras SAE, van de Kaa CA, van der Poel HG, Michalides RJ, Debruyne FMJ, Schalken JA. Comparative analysis of p53 mutations in bladder washings and histologic specimens. *Am J Clin Pathol* 1998;110:547-52.
154. Schamhart DHJ, de Reijke TM, van der Poel HG, Witjes JA, de Boer EC, Kurth KH, Schalken JA. The BARD BTA test: its mode of action, sensitivity, and specificity, compared to cytology of voided urine, in the diagnosis of superficial bladder cancer. *Eur Urol* 1998;34:99-106.
155. Witjes JA, van der Poel HG, van Balken MR, Debruyne FMJ, Schalken JA. Urinary NMP22<sup>TM</sup> and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer. *Eur Urol* 1998;33:387-391.
156. Boon ME, Marres EM, van der Poel HG. Combining QUANTICYT karyometric analysis with architectural confocal-aided cytology to prognosticate superficial bladder cancer. *Diagn Cytopathol* 18:10-17, 1998.
157. Tamimi Y, van der Poel HG, Karthaus HF, Debruyne FM, Schalken JA. A retrospective study of high mobility group protein I(Y) as progression marker for prostate cancer determined by in situ hybridization. *Br J Cancer* 1996;74(4): 573-8.
158. Vet JA, Witjes JA, Marras SA, Hessels D, van der Poel HG, Debruyne FMJ, Schalken JA. Predictive value of p53 mutations analyzed in bladder washings for progression of high-risk superficial bladder cancer. *Clin Cancer Res* 1996;2:1055-1061.
159. Boon ME, van der Poel HG, Tan CJ, Kok LP. Effect of embedding methods versus fixative type on karyometric measures. *Anal Quant Cytol Histol* 1994;16(2): 131-6.
160. Tamimi Y, van der Poel HG, Denyn MM, Umbas R, Karthaus HF, Debruyne FM, Schalken JA. Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. *Cancer Res* 1993;53(22): 5512-6.

161. Zeppa P, van der Poel HG, Boon ME, Kurniawan AN, Kok LP. A model for quantitative follow-up studies of cervical lesions. *Diagn Cytopathol* 1992;8(1): 8-17.
162. Muizelaar JP, van der Poel HG, Li ZC, Kontos HA, Levasseur JE. Pial arteriolar vessel diameter and CO<sub>2</sub> reactivity during prolonged hyperventilation in the rabbit. *J Neurosurg* 1988;69(6):923-7.



Henk van der Poel